Actualités

Un article intitulé " Clinical and Organizational Impacts of Medical Ordering Settings on Patient Pathway and Community Pharmacy Dispensing Process: The Prospective ORDHOSPIVILLE Study" vient de paraître dans " Pharmacy "

Auteurs : Justine Clarenne, Julien Gravoulet, Virginie Chopard, Julia Rouge, Amélie Lestrille, François Dupuis, Léa Aubert, Sophie Malblanc, Coralie Barbe, Florian Slimano et Céline Mongaret

Pharmacy 2022, 10(1), 2; https://doi.org/10.3390/pharmacy10010002

Abstract

Un article intitulé " Analytical Methods for the Quantification of Selenium Species in Biological Matrix: Where are We?"

Auteurs : Rama Alhasan , Caroline Perrin-Sarrado, Claus Jacob et Caroline Gaucher

Current Nutraceuticals, 2022, 3, 1. https://doi.org/10.2174/2665978602666211117154655

Abstract

Objective: Over the years, scientific investigations have proven the importance of selenium as an essential element for mammals, emphasizing its activity against many diseases and even its prophylactic effects. It is also established now that a malconsumption of selenium can be harmful. Therefore, the nature and the concentration of selenium and its derivatives found in the diet, the body, and even in the environment, for example, in the soil, should be determined carefully.

Methods: In this review, analytical methods for speciation and determination of selenium concentrations in biological samples are summarized.

Results: Methods ranging from routine to cutting-edge are explored, focusing on their analytical characteristics, such as specificity for discrete selenium species, sensitivity, accuracy, reproducibility, and skills required.

Conclusion: There are already numerous studies regarding the analysis of selenium species. Beyond the method employed for actual measurements, we propose to review the preanalytic steps for sample handling in biological matrices, which directly affect results that will be more accurate with careful pretreatment. Furthermore, to reach better outcomes in terms of the identification of selenium species, different combinations of techniques might be the answer. We highlight here the last and the cutting-edge methods to identify and quantify selenium such as, high-performance liquid chromatography combined to inductively coupled plasma mass spectrometry (HPLC-ICP-MS), hydride generation atomic absorption spectrometry (HG-AAS), hydride-generation combined to atomic fluorescence spectrometry (HG-AFS), or to inductively coupled plasma optical emission spectrometry (HG-ICP-OES). This review emphasizes the importance of such investigations and the need to achieve reliable, safe, and effective quantification and methods of determination.

Un article intitulé "Monitoring of Gold Biodistribution from Nanoparticles Using a HPLC-Visible Method." vient de paraître dans "Separations"

Auteurs : Chaigneau, T.; Pallotta, A.; Benaddi, F.Z.; Sancey, L.; Chakir, S.; Boudier, A.; Clarot, I.

Separations 2021, 8, 215. https://doi.org/10.3390/separations8110215

Abstract

There is intensive research using gold nanoparticles for biomedical purposes, which have many advantages such as ease of synthesis and high reactivity. Their possible small size (<10 nm) can lead to the crossing of biological membranes and then to problematic dissemination and storage in organs that must be controlled and evaluated. In this work, a simple isocratic HPLC method was developed and validated to quantify the gold coming from nanoparticles in different biological samples. After a first carbonization step at 900 °C, the nanoparticles were oxidized by dibroma under acidic conditions, leading to tetrachloroaurate ions that could form ion pairs when adding rhodamine B. Finally, ion pairs were extracted and rhodamine B was evaluated to quantify the corresponding gold concentration by reversed-phase HPLC with visible detection. The method was validated for different organs (liver, spleen, lungs, kidneys, or brain) and fluids (plasma and urine) from rats and mice. Lastly, the developed method was used to evaluate the content of gold in organs and fluids after intravenous (IV) injection of nanoparticles.

Justine Bonetti soutiendra sa thèse de doctorat intitulée "Potentiel thérapeutique des S-nitrosothiols dans la prévention de l'athérosclérose : modulation de la métaplasie des monocytes et des cellules musculaires lisses" dans la salle de réunion du laboratoire de l'équipe ce mercredi 3 novembre à 14h.

Un article intitulé "Rapamycin-loaded Poly(lactic-co-glycolic) acid nanoparticles: Preparation, characterization, and in vitro toxicity study for potential intra-articular injection" vient de paraître dans "International Journal of Pharmaceutics"

Auteurs : Elise Pape, Marianne Parent, Astrid Pinzano, Anne Sapin-Minet, Christel Henrionnet, Pierre Gillet, Julien Scala-Bertola, Nicolas Gambier

International Journal of Pharmaceutics, Elsevier, 2021, 609, pp.121198. https://doi.org/10.1016/j.ijpharm.2021.121198

Abstract : 

Osteoarthritis (OA) is the most common degenerative joint disease. Rapamycin is a potential candidate for OA treatment by increasing the autophagy process implicated in its physiopathology. To optimize Rapamycin profit and avoid systemic side effects, intra-articular (i.a.) administration appeared helpful. However, Rapamycin's highly hydrophobic nature and low bioavailability made it challenging to develop purpose-made drug delivery systems to overcome these limitations. We developed Rapamycin-loaded nanoparticles (NPs) using poly (lactic-co-glycolic acid) by emulsion/evaporation method. We evaluated these NPs' cytocompatibility towards cartilage (chondrocytes) and synovial membrane cells (synoviocytes) for a potential i.a. administration. The in vitro characterization of Rapamycin-loaded NPs had shown a suitable profile for an i.a. administration. In vitro biocompatibility of NPs was highlighted to 10 µM of Rapamycin for both synoviocytes and chondrocytes, but significant toxicity was observed with higher concentrations. Besides, synoviocytes are more sensitive to Rapamycin-loaded NPs than chondrocytes. Finally, we observed in vitro that an adapted formulated Rapamycin-loaded NPs could be safe at suitable i.a. injection concentrations. The toxic effect of Rapamycin encapsulated in these NPs on both articular cells was dose-dependent. After Rapamycin-loaded NPs i.a. administration, local retention, in situ safety, and systemic release should be evaluated with experimental in vivo models.

Un article intitulé "Recent progress in the toxicity of nitric oxide-releasing nanomaterials" vient de paraître dans "Materials Advances"

Auteurs : Joana Claudio Pieretti, Milena T Pelegrino, Ariane Boudier, Amedea Barozzi Seabra

Materials Advances, Royal Society of Chemistry, 2021, https://doi.org/10.1039/D1MA00532D

Abstract : 

Nitric oxide (NO) is a signaling molecule controlling important biological processes. Depending on its concentration, location and cellular environment, NO can have protective or toxic effects. As NO is a free radical, several classes of NO donors/generators have been prepared and combined with nanomaterials, in particular with polymeric nanoparticles. Engineered nanoparticles are attractive nanocarriers extensively used in biomedical applications, in particular in cancer biology due to their ability to promote a site-target therapeutic effect, with minimum side effects to health tissues. NO-releasing nanoparticles can have direct toxic effects to tumor cells, or it can promote cancer cells sensitization to traditional cancer treatments. The combination of NO-releasing nanoparticles with conventional anticancer therapies is a promising approach in the reversion of multidrug resistance (MDR) cells. This review presents and discusses the recent progress in the cytotoxicity (tumoral and non-tumoral cell lines) of NO-releasing polymeric and/or polymer-coated nanomaterials and the in vivo biocompatibility of NO-releasing nanoparticles. Moreover, the ability of these nanoparticles to combat MDR, their mechanisms of toxicity and drawbacks are also discussed.

Un article intitulé "The Impact of Multiple Functional Layers in the Structure of Magnetic Nanoparticles and Their Influence on Albumin Interaction" vient de paraître dans "International Journal of Molecular Sciences".

Auteurs : Pieretti, J.C.; Beurton, J.; Munevar, J.; Nagamine, L.C.C.M.; Le Faou, A.; Seabra, A.B.; Clarot, I.; Boudier, A.

Int. J. Mol. Sci. 2021, 22, 10477. https://doi.org/10.3390/ijms221910477

Abstract

In nanomedicine, hybrid nanomaterials stand out for providing new insights in both the diagnosis and treatment of several diseases. Once administered, engineered nanoparticles (NPs) interact with biological molecules, and the nature of this interaction might directly interfere with the biological fate and action of the NPs. In this work, we synthesized a hybrid magnetic nanostructure, with antibacterial and antitumoral potential applications, composed of a magnetite core covered by silver NPs, and coated with a modified chitosan polymer. As magnetite NPs readily oxidize to maghemite, we investigated the structural properties of the NPs after addition of the two successive layers using Mössbauer spectroscopy. Then, the structural characteristics of the NPs were correlated to their interaction with albumin, the major blood protein, to evidence the consequences of its binding on NP properties and protein retention. Thermodynamic parameters of the NPs–albumin interaction were determined. We observed that the more stable NPs (coated with modified chitosan) present a lower affinity for albumin in comparison to pure magnetite and magnetite/silver hybrid NPs. Surface properties were key players at the NP–biological interface. To the best of our knowledge, this is the first study that demonstrates a correlation between the structural properties of complex hybrid NPs and their interaction with albumin.

Jordan BEURTON soutiendra sa thèse de doctorat intitulée "Optimisation physico-chimique de films fonctionnalisés pour des applications cardiovasculaires" le vendredi 17 septembre à 13h30 dans la salle de réunion de l'équipe de recherche.

Le jury est composé de :

- M. Nicolas BLANCHEMAIN (Rapporteur, PR, U1008 INSERM, Faculté de Pharmacie de Lille, Lille)

- Mme Sophie DEMOUSTIER-CHAMPAGNE (Rapporteur, PR, IMCN/BSMA, Université Catholique de Louvain, Louvain-la-Neuve)

- Mme Corine GERARDIN (Examinateur, DR, Institut Charles Gerhardt, UMR 5253 CNRS, Université de Montpellier, Montpellier)

- M. Gregory FRANCIUS (Examinateur, DR, LCPME UMR 7564 CNRS, Université de Lorraine, Nancy)

- Mme Ariane BOUDIER (Examinateur, PR, EA 3452 CITHEFOR Université de Lorraine, Nancy, Directrice de thèse)

- M. Philippe LAVALLE (Examinateur, DR, U 1121 INSERM, Université de Strasbourg, Strasbourg, Co-directeur de thèse)

- M. Benoit FRISCH (Membre invité, DR, UMR7199 CNRS, Université de Strasbourg, Strasbourg)

- M. Raphaël DUVAL (Membre invité, PR, L2CM UMR 7053 CNRS, Université de Lorraine, Nancy)

Un nouvela article intitulé "Room-temperature growth of covalent organic framework as stationary phase for open-tubular capillary electrochromatography" vient de paraître dans "Analyst".

Auteurs : Qiaoyan Li, Zhengtao Li, Yuanyuan Fu, Igor Clarot, Ariane Boudier, Zilin Chen

Analyst, Royal Society of Chemistry, 2021, https://doi.org/10.1039/D1AN01402A

Abstract :

Covalent organic frameworks (COFs) is a class of porous materials with high surface area, high porosity, good stability and tunable structure that have been neatly used in the separation area. In this work, we have proposed the in-situ synthesis of a novel COF composed of 4,4',4''-(1,3,5-Triazine-2,4,6-triyl)trianiline (Tz) and 1,4-dihydroxyterephthalaldehyde (Da) onto the capillary inner surface for electrochromatographic separation. Fourier transform infrared spectroscopy (FT-IR), elemental analysis (EA) and scanning electron microscopy (SEM) have been facilitated to characterize the prepared capillary columns. The COF (TzDa) modified OT-CEC column exhibited satisfactory separation selectivity towards neutral compounds (such as chlorobenzenes and alkylbenzenes), acidic and basic compounds (such as phenols and anilines), food additives (vanillin and its analogues) and small biomolecules (such as amino acids and polypeptides). Furthermore, the TzDa modified capillary was quite stable and repeatable. The relative standard deviations for retention times of the test analytes (alkylbenzenes) were as follow: for intra-day (n = 3) runs (≤ 1.74%), inter-day (n = 3) runs (≤ 2.25%) and column to columns (n = 3) (≤ 4.83%). This new type of COF-based stationary phase has tremendous potential in separation science.

Le projet de recherche collaborative (PRC) SMILING a été sélectionné définitivement pour un financement par l'ANR.

Il s'agit d'un projet dont Caroline GAUCHER, MCF au sein du laboratoire, est partenaire.

Évaluation préclinique chez le gros animal d’un substitut vasculaire construit par ingénierie tissulaire à partir du cordon ombilical humain

Preclinical evaluation, in a big animal model, of a tissue-engineered vascular substitute derived from the human umbilical cord

SMall dIameter vascuLar cellularIzed humaN Graft (SMILING)

Porteur Pr V Decot, PU-PH (UTCT, CHRU Nancy)

Partenaires :

• Pr P Menu et Dr Reine El Omar (UMR 7365 IMoPA)
• Dr C Gaucher (EA 3452)
• Pr N Tran et Pr P Maureira (UMR_S 1116 DCAC, Ecole de Chirurgie de Nancy Lorraine)

Les maladies cardiovasculaires représentent 31% des décès mondiaux. Leur traitement chirurgical repose sur des greffes vasculaires afin de contourner une sténose. Bien que les vaisseaux autologues soient la règle d'or, la disponibilité limitée des greffes vasculaires de petit diamètre est un réel problème de santé publique. Nous avons mis au point un substitut vasculaire innovant de petit diamètre (SMILING), entièrement construit à partir du cordon ombilical humain : la matrice issue d'une artère ombilicale décellularisée, recouverte de gelée de Wharton et cellularisée avec des cellules souches mésenchymateuses. Pour envisager un essai clinique de phase I, ce projet vise à produire SMILING conformément aux normes françaises de bonnes pratiques de fabrication (BPF) imposées par l'ANSM et à le valider en tant que substitut lors d’un pontage coronarien chez le porc. Le projet «SMILING» développera un produit thérapeutique pour plusieurs applications possibles en médecine régénérative.

Cardiovascular disease accounts for 31% of global deaths. Their surgical treatment is based on vascular grafts in order to bypass stenosis. Although autologous vessels are the gold standard, the limited availability of small diameter vascular grafts is a real public health issue. We have developed an innovative small diameter vascular substitute (SMILING), entirely constructed from the human umbilical cord: the matrix resulting from a decellularized umbilical artery, covered with Wharton's jelly and cellularized with mesenchymal stem cells. To consider a phase I clinical trial, this project aims to produce SMILING in accordance with French standards of good manufacturing practices (GMP) imposed by the ANSM and to validate it as a substitute during coronary bypass surgery in pigs. The “SMILING” project will allow the development of a therapeutic product for several possible applications in regenerative medicine.